Add Company
Join Now

NeuroSense Therapeutics Revenue and Competitors

License our Company Data API

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • NeuroSense Therapeutics's estimated annual revenue is currently $5.3M per year.(i)
  • NeuroSense Therapeutics's estimated revenue per employee is $155,000

Employee Data

  • NeuroSense Therapeutics has 34 Employees.(i)
  • NeuroSense Therapeutics grew their employee count by 0% last year.

NeuroSense Therapeutics's People

NameTitleEmail/Phone
1
CEO & Co-FounderReveal Email/Phone
2
Chief Financial OfficerReveal Email/Phone
3
Chief Medical OfficerReveal Email/Phone
4
Chief Technology OfficerReveal Email/Phone
5
Chief Operating OfficerReveal Email/Phone
6
VP Research and DevelopmentReveal Email/Phone
7
VP CMCReveal Email/Phone
8
VP QA and ComplianceReveal Email/Phone
9
VP Business DevelopmentReveal Email/Phone
10
VP Regulatory AffairsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$12.7M82-45%$107.3MN/A
#2
$0.2M1-50%N/AN/A
#3
$6.2M4021%N/AN/A
#4
$42.2M2184%$165MN/A
#5
$14.6M94-37%$312.8MN/A
#6
$0.3M2-67%N/AN/A
#7
$235M366-5%$340.9MN/A
#8
$56M289-7%$7.6MN/A
#9
$4.7M6136%N/AN/A
#10
$2M138%N/AN/A
Add Company

What Is NeuroSense Therapeutics?

Advancing research, development and therapy for ALS and additional CNS indications.\n\nNeuroSense Therapeutics Ltd. (NASDAQ: NRSN) is a clinical stage Biotech company focusing on the development of a ground-breaking treatment for ALS patients, as well as other neurodegenerative diseases.\n\nCurrently in conducting a Phase 2b, double-blind, randomized, placebo controlled clinical study in ALS patients globally.\n$NRSN

keywords:N/A

N/A

Total Funding

34

Number of Employees

$5.3M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.7M3426%$85.2M
#2
$5.3M346%N/A
#3
$7.3M34-19%N/A
#4
$35M34N/AN/A
#5
$5.3M346%N/A